Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill'...
The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus n...
-Kezar Life Sciences, Inc. a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated di...
Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patien...
- First subject received unilateral administration of NRTX-1001 in a new non-MTS cohort; no significant surgical complications or adverse events re...
Avobis Bio LLC, a clinical-stage company developing implantable cell therapies, announced that the U.S. Food and Drug Administration ("FDA") has gr...
SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseases Phase 1b trial to...
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fas...
Polyrizon Ltd., a biotechnology company focusing on the development of intranasal products announced the submission of its full pre-submission (Pre-Sub) ...
Global pharma major Lupin Limited announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Ab...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...
Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA 3 phase 3 study that demonstrate...
Piramal Pharma Solutions extended its robust CDMO capabilities to George Medicines to develop WIDAPLIK. WIDAPLIK is the first and only FDA-approved tr...
MannKind Corporation announced that United Therapeutics Corporation has exercised its option—granted under the companies’ 2018 lic...
© 2026 Biopharma Boardroom. All Rights Reserved.
